NCT04517227View on ClinicalTrials.gov

The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)

NANot yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 31, 2021

Primary Completion Date

June 30, 2025

Study Completion Date

October 31, 2025

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Durvalumab

Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.

PROCEDURE

Transcatheter Hepatic Arterial Chemoembolization (TACE)

TACE techniques have been described in the NCCN and ESMO-ESDO guidelines, including cTACE and DEB-TACE.

PROCEDURE

Ablation

In this study, thermal ablation could be conducted with radiofrequency (RFA) or microwave (MWA).

All Listed Sponsors
lead

Fudan University

OTHER

NCT04517227 - The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD) | Biotech Hunter | Biotech Hunter